ABVC - ABVC Biopharma Inc

ABVC - ABVC Biopharma Inc

https://www.abvcpharma.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

EQS-News: ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology

Business Insider • 2 months, 2 weeks ago • score: 0.17

ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology

EQS-News: ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment

Business Insider • 2 months, 3 weeks ago • score: 0.33

EQS-News: ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma. Commits to Up to $20 Million in Total Investment ...

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 - ABVC BioPharma ( NASDAQ:ABVC )

Benzinga • 8 months, 3 weeks ago • score: 0.20

FREMONT, Calif., Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- ABVC BioPharma, Inc.

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

GlobeNewswire • 9 months ago • score: 0.25

FREMONT, Calif., Dec. 11, 2024 ( GLOBE NEWSWIRE ) -- ABVC BioPharma, Inc. ( NASDAQ: ABVC ) , a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS ( central nervous system ) , and oncology/hematology, announced the receipt of a $200,000 cash payment ...

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

GlobeNewswire • 10 months, 3 weeks ago • score: 0.31

FREMONT, Calif., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- ABVC BioPharma, Inc. ( NASDAQ: ABVC ) , a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS ( central nervous system ) , and oncology/hematology, today announced the receipt of an additional ...

Why ABVC BioPharma Stock Is Up Today - ABVC BioPharma ( NASDAQ:ABVC )

Benzinga • 1 year, 5 months ago • score: 0.47

ABVC BioPharma, Inc. ABVC shares are trading higher Tuesday after the company announced it has entered into a global licensing agreement with ForSeeCon Eye Corporation for the company's ophthalmology pipeline.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.

52W High

$5.48

52W Low

$0.40

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.27

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.90

EV/Revenue (<3 favorable)

164.15

P/S (TTM) (<3 favorable)

161.26

P/B (<3 favorable)

9.00

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

11.73%

Institutions (25–75% balanced)

1.56%

Shares Outstanding

23,541,800

Float

20,049,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

391,240

Gross Profit (TTM)

390,950

EPS (TTM)

-0.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-10.21%

ROE (TTM) (>15% strong)

-0.53%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.09

Momentum

Bearish momentum

Value

-0.0720

Previous

-0.0865

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025